Gene: B4GALT7
Official Full Name: beta-1,4-galactosyltransferase 7provided by HGNC
Gene Summary: This gene is a member of the beta-1,4-galactosyltransferase (beta4GalT) family. Family members encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose. Each beta4GalT member has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins, they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus which then remains uncleaved to function as a transmembrane anchor. The enzyme encoded by this gene attaches the first galactose in the common carbohydrate-protein linkage (GlcA-beta1,3-Gal-beta1,3-Gal-beta1,4-Xyl-beta1-O-Ser) found in proteoglycans. This enzyme differs from other beta4GalTs because it lacks the conserved Cys residues found in beta4GalT1-beta4GalT6 and it is located in cis-Golgi instead of trans-Golgi. Mutations in this gene have been associated with the progeroid form of Ehlers-Danlos syndrome. [provided by RefSeq, Oct 2009]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01779 | B4GALT7 Knockout cell line (HeLa) | Human | B4GALT7 | 1:3~1:6 | Negative | Online Inquiry |
KO01780 | B4GALT7 Knockout cell line (HCT 116) | Human | B4GALT7 | 1:2~1:4 | Negative | Online Inquiry |
KO01781 | B4GALT7 Knockout cell line (HEK293) | Human | B4GALT7 | 1:3~1:6 | Negative | Online Inquiry |
KO01782 | B4GALT7 Knockout cell line (A549) | Human | B4GALT7 | 1:3~1:4 | Negative | Online Inquiry |
B4GALT7 Gene Knockout Cell Lines are specialized cellular models developed to facilitate the study of the B4GALT7 gene, which plays a crucial role in the biosynthesis of glycosaminoglycans and glycoproteins. By creating a knockout of the B4GALT7 gene, these cell lines enable researchers to dissect the gene's function and its implications in various biological processes and pathologies. The knockout mechanism involves the targeted disruption of the gene using CRISPR/Cas9 technology, resulting in a model that effectively mimics loss-of-function mutations relevant to human diseases.
The key functions of B4GALT7 include the modification of glycoproteins and the synthesis of extracellular matrix components. This is vital for cell-cell communication, tissue development, and repair. Understanding how the knockout of B4GALT7 affects these processes can shed light on its involvement in conditions such as congenital disorders, cancer, and fibrosis. In both research and clinical settings, these cell lines serve as powerful tools for elucidating the molecular pathways influenced by B4GALT7, thus aiding in the identification of potential therapeutic targets.
Compared to traditional methods of gene editing, such as homologous recombination, the CRISPR/Cas9 system utilized in our B4GALT7 Gene Knockout Cell Lines offers high efficiency, specificity, and ease of use. The targeted nature of this approach minimizes off-target effects, enabling scientists to obtain robust and reproducible results. Additionally, the availability of these cell lines accelerates the research process, providing immediate access to valuable models that would otherwise require extensive development time.
For researchers and clinicians, the B4GALT7 Gene Knockout Cell Lines represent a significant advancement, allowing for deeper investigations into gene function and the development of innovative treatment strategies. Our company, with its commitment to providing high-quality biological products and expertise in gene editing technologies, ensures that you have the essential resources needed to propel your research forward. By leveraging our B4GALT7 Gene Knockout Cell Lines, you are positioned to make impactful discoveries in the field of genetics and molecular biology.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.